Sun Pharma Finalizes $416M Deal for Checkpoint Therapeutics, Inc. (CKPT)

Officially completing its acquisition of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT), Sun Pharmaceutical Industries Ltd. has expanded its immuno-oncology footprint. The deal, announced earlier this year, is valued at approximately $416 million. It includes the purchase of all outstanding shares at $4.10 per share, with the possibility of an additional $0.70 per share through contingent value rights (CVRs).

Sun Pharma Finalizes $416M Deal for Checkpoint Therapeutics, Inc. (CKPT)

A researcher in a lab coat analyzing the effects of PD-L1 on GITR Expressing Cells to advance the targeted oncology.

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)’s landmark FDA approval for UNLOXCYT played a notable role in the acquisition, with the drug being the only anti-PD-L1 therapy cleared for treating advanced cutaneous squamous cell carcinoma. The drug, through the acquisition, could potentially enhance Sun Pharma’s position in onco-dermatology, which has been prioritized by the company in recent years. Dilip Shanghvi, Chairman & Managing Director of Sun Pharma, made the following comment:

“By adding UNLOXCYT, we will be able to leverage our leadership in the onco-derm space to help patients access an important treatment option while growing our product portfolio.”

The merger arrives as Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)’s market cap stands at $370.71 million. With the deal valued at $416 million, the premium paid by Sun Pharma signals confidence in the company’s long-term assets, including UNLOXCYT and olafertinib.

In its Q1 2025 financial update, Checkpoint Therapeutics, Inc. (NASDAQ:CKPT), in addition to mentioning the UNLOXCYT milestone, has reported the ongoing developments in its pipeline, including olafertinib for non-small cell lung cancer.

While we acknowledge the potential of CKPT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CKPT and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Unstoppable Dividend Stocks to Buy Now and 11 Oversold Global Stocks to Buy According to Hedge Funds.

Disclosure: None.